NASDAQ
12.72USD
-0.16 (-1.24%)
We have scored 17 news catalysts on ORIC Pharmaceuticals, Inc. (ORIC) over the past 12 months. The biggest single-day move next to one of them came Jun 1, 2026, when ORIC closed +6.3%: “ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential”. Coverage across the window leans mixed (average ticker sentiment +0.03). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.3B
P/E
—
EPS
—
Beta
0.99
52W range
7.23-14.93
Day range
12.65–12.91
Open
12.81
Prev close
12.88
Volume
275.1K
Avg volume
1.6M
Dividend
0.00
IPO
2020-04-24
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about ORIC Pharmaceuticals, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ORIC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
